With GLP-1 drugs gaining widespread popularity, the coming years will see unprecedented attention on obesity drug development. However, next-generation therapeutics such as amylin analogues, multi-target agonists, and gene therapies are far more complex, and traditional preclinical platforms may struggle to deliver the predictive accuracy needed. Protheragen Obesity has announced a new tiered system of obesity models designed to close this translational gap.
Traditional diet-induced obesity (DIO) models focus heavily on macroscopic endpoints like body weight and food intake, while overlooking critical pharmacodynamic dimensions such as body composition, energy metabolic homeostasis, and target organ histopathology. This likely contributes to the high attrition rate of compounds that perform well preclinically but fail in clinical trials. Meanwhile, CRISPR/Cas9 gene editing now enables precise recapitulation of human obesity-associated mutations (e.g., LEP, LEPR, MC4R pathways), providing validation platforms for antibodies and gene therapies.
Protheragen Obesity's system includes in vitro cell models (3T3-L1 differentiation, primary adipocyte co-culture), gene-edited models (single/multi-gene mutations, humanized replacements), diet-induced models (high-fat, high-sugar, with or without STZ for diabetes comorbidities), and chemically or surgically induced models. Each model is equipped with comprehensive metabolic phenotyping, including DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance tests, and histopathological examination.
The company operates under a GLP-compliant quality management system. For DIO studies running 8 to 16 weeks, the model induction success rate exceeds 90%. Gene-edited models come with genotyping reports, copy number and integration site analysis, and germline transmission validation. All study reports meet FDA and NMPA requirements for IND-enabling pharmacology submissions.
Protheragen Obesity offers three collaboration models: full-service outsourcing, modular services, and co-development partnerships. Every engagement begins with a consultation phase where the technical team customizes the optimal model strategy based on the molecular modality, mechanism of action, and regulatory pathway. With extensive experience, the company has supported dozens of biopharmaceutical firms in completing obesity drug programs from target validation to IND submission.
For more information, visit Protheragen Obesity.
